8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

_____________________

FORM 8-K

_____________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): March 23, 2016

Concert Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware	001-36310	20-4839882
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

99 Hayden Avenue, Suite 500 Lexington, Massachusetts	02421
(Address of Principal Executive Offices)	(Zip Code)

Registrant’s telephone number, including area code: (781) 860-0045

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On March 22, 2016, the Board of Directors (the “Board”) of Concert Pharmaceuticals, Inc. (the “Company”) elected Meghan FitzGerald to serve as a Class II director until the Company’s 2016 Annual Meeting of Stockholders and thereafter until her successor is duly elected and qualified. Ms. FitzGerald will serve on the Compensation Committee of the Board.

Ms. FitzGerald will receive compensation for her board service as a non-employee director in accordance with the Company’s previously disclosed director compensation program, including a one-time nonqualified stock option that was granted to Ms. FitzGerald under the Company’s 2014 Stock Incentive Plan to purchase 25,000 shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), with an exercise price of $13.68 per share, equal to the closing price of the Common Stock on the NASDAQ Global Market on the grant date. The option will vest in equal quarterly installments over a three-year period measured from the date of grant, subject to Ms. FitzGerald’s continued service as a director, and will become exercisable in full upon a change in control of the Company. The Company also entered into its standard form of indemnification agreement with Ms. FitzGerald.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

The Exhibits to this Current Report on Form 8-K are listed in the Exhibit Index attached hereto.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		CONCERT PHARMACEUTICALS, INC.
	By:	/s/ Roger D. Tung
Date: March 23, 2016		Roger D. Tung
		President and Chief Executive Officer

EXHIBIT INDEX

Exhibit No.	Description
99.1	Press Release issued by Concert Pharmaceuticals, Inc., dated March 23, 2016

EX-99.1

EXHIBIT 99.1

NEWS RELEASE

For additional information contact:

Justine Koenigsberg (investors)

Concert Pharmaceuticals, Inc.

(781) 674-5284

ir@concertpharma.com

Kathryn Morris (media)

The Yates Network

(845) 635-9828

FOR IMMEDIATE RELEASE

Concert Pharmaceuticals Names Meghan FitzGerald to its Board of Directors

Lexington, MA (March 23, 2016) -- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) announced today that Meghan FitzGerald has been appointed to its Board of Directors and will serve as a member of its compensation committee effective March 22, 2016.

“We are delighted to welcome Meg to our Board of Directors,” said Roger Tung, Ph.D., President and Chief Executive Officer of Concert Pharmaceuticals. “She is an accomplished executive with broad expertise in the healthcare industry who will provide important breadth to our Board as we advance and broaden our pipeline of innovative therapeutics.”

“Concert is an innovative biotechnology company pioneering a technology that combines potentially significant reduction in development risk with the opportunity to meaningfully enhance patient care with differentiated and effective new medicines,” said Ms. FitzGerald.  “I am excited to join the Board of this fast-paced company and look forward to sharing my insights and experiences with the talented management team.”

Meg FitzGerald currently serves as the Executive Vice President of Strategy and Policy at Cardinal Health, Inc. Prior to this role, she was the president of Cardinal Health Specialty Solutions, a specialty healthcare business that offers services for healthcare providers, payers, and pharmaceutical and biotech industries.

Prior to joining Cardinal Health, Ms. FitzGerald was senior vice president of New Markets International Division and Business Development at Medco Health Solutions, Inc., where she was responsible for leading business development efforts in the United States and internationally. She previously held positions of increasing responsibility at Pfizer Global Pharmaceuticals, where she supported business strategies and operations, including the implementation of ten-year lifecycle plans for various pharmaceutical products such as Celebrex. Ms. FitzGerald has also held marketing positions at Merck and Sanofi-Synthelabo.

She is a member of the board of directors for SeniorLink, a provider of in home care and support for elders and individuals with disabilities, and GELESIS, a privately held biotechnology company. She recently accepted an invitation to join the World Economic Forum’s Global Agenda Council on Ageing.

Ms. FitzGerald also serves as a member of the adjunct faculty at Columbia University in New York, teaching The Business of Healthcare. Ms. FitzGerald obtained a Doctor of Public Health (DrPH) degree at New York Medical College, focusing on health policy. She earned a master’s degree in public health from Columbia University and a bachelor's degree in nursing from Fairfield University.

About Concert

Concert Pharmaceuticals is a clinical stage biopharmaceutical company focused on applying its DCE Platform® (deuterated chemical entity platform) to create novel small molecule drugs. This approach starts with approved drugs, advanced clinical candidates or previously studied compounds that have the potential to be improved with deuterium substitution to enhance clinical safety, tolerability and efficacy. The Company is developing a broad pipeline targeting CNS disorders, genetic diseases and inflammatory diseases. For more information, please visit www.concertpharma.com.

Concert Pharmaceuticals Inc., the CoNCERT Pharmaceuticals Inc. logo and DCE Platform are registered trademarks of Concert Pharmaceuticals, Inc.